Joseph A. Tangrea

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index8.5kcitations108works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Lipids, and Metabolism(24), Antioxidant Activity and Oxidative Stress(18), Nutritional Studies and Diet(15), Estrogen and related hormone effects(14), Melanoma and MAPK Pathways(11)

Publications108 total

Supplementary Figures 1 - 8 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Materials and Methods from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Tables 1 - 2 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Figures 1 - 8 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Materials and Methods from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Tables 1 - 2 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Figure Legends from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Supplementary Figure Legends from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
Data from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
2023Open Access
General Introduction: Rationale for the Nutritional Prevention of Cancer
2021· 1 cited
Pilot Study on the Bioactivity of Vitamin D in the Skin after Oral Supplementation
Cancer Prevention Research·2015· 13 citedOpen Access
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer
Journal of Oncology Pharmacy Practice·2014· 2 citedOpen Access
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology
Cancer Prevention Research·2014· 29 citedOpen Access
A Randomized, Double-Blind, Placebo-Controlled Phase II ClinicalTrialofLovastatinforVariousEndpointsofMelanoma Pathobiology
2014
Prostate Cancer Prevention: Agent Development Strategies
Recent results in cancer research/Recent Results in Cancer Research·2014· 3 cited
Prostate cancer prevention
Current Opinion in Oncology·2013· 20 cited
Randomized, double‐blind, placebo‐controlled trial of sulindac in individuals at risk for melanoma
Cancer·2012· 21 citedOpen Access
163 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF POLYPHENON E IN PROSTATE CANCER PATIENTS BEFORE RADICAL PROSTATECTOMY: EVALUATION OF POTENTIAL CHEMOPREVENTIVE ACTIVITIES
The Journal of Urology·2012· 3 cited
A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients
Cancer Prevention Research·2012· 90 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Demetrius Albanes(21), Philip R. Taylor(21), Jarmo Virtamo(18), Karen Woodson(14), Matti Rautalahti(8), Arthur Schatzkin(8), Pirjo Pietinen(8), Terryl J. Hartman(7), Michael Barrett(5), Nea Malila(5), Joanne F. Dorgan(5), D Ratnasinghe(5), Anne M. Hartman(4), Mikko Virtanen(4), K. Woodson(4), Sanford M. Dawsey(3), Olli P. Heinonen(3), Lisa Kahle(3), June K. Robinson(3), Jeffrey Hanson(3)